Richard F Pollock

List of Publications by Year
in descending order

52	669	687363 13	642732 23
papers	citations	h-index	g-index

52	52	52	851
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Patient safety during procedural sedation using capnography monitoring: a systematic review and meta-analysis. BMJ Open, 2017, 7, e013402.	1.9	71
2	Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant. PLoS ONE, 2016, 11, e0160421.	2.5	63
3	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health, 2018, 21, 724-731.	0.3	63
4	Impact of Stigma on People Living with Chronic Hepatitis B . Patient Related Outcome Measures, 2020, Volume 11, 95-107.	1.2	46
5	Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Review of Hematology, 2020, 13, 187-195.	2.2	34
6	Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden. Journal of Medical Economics, 2013, 16, 1442-1452.	2.1	25
7	Evaluating the costâ€effectiveness of laparoscopic adjustable gastric banding versus standard medical management inÂobese patients with type 2 diabetes in the <scp>UK</scp>. Diabetes, Obesity and Metabolism, 2013, 15, 121-129.	4.4	25
8	Long-Acting Insulin Analogs: A Review of “Real-World” Effectiveness in Patients with Type 2 Diabetes. Current Diabetes Reviews, 2011, 7, 61-74.	1.3	19
9	A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment. Expert Review of Hematology, 2019, 12, 129-136.	2.2	19
10	Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2575-2587.	2.5	19
11	The cost effectiveness of rapid-acting insulin aspart compared with human insulin in type 2 diabetes patients: an analysis from the Japanese third-party payer perspective. Journal of Medical Economics, 2011, 14, 36-46.	2.1	16
12	Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients. Advances in Therapy, 2016, 33, 345-356.	2.9	16
13	Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States. Diabetes Therapy, 2018, 9, 951-961.	2.5	16
14	A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 475-483.	1.9	13
15	An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in Therapy, 2018, 35, 2128-2137.	2.9	13
16	A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom. Journal of Medical Economics, 2020, 23, 751-759.	2.1	13
17	Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK. Expert Opinion on Drug Delivery, 2017, 14, 1439-1446.	5.0	11
18	A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark. Journal of Medical Economics, 2017, 20, 213-220.	2.1	11

#	Article	IF	Citations
19	DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basalâ€"Bolus Regimens for Type 2 Diabetes in the UK. Diabetes Therapy, 2018, 9, 1217-1232.	2.5	11
20	Evaluating the economic implications of non-adherence and antibody-mediated rejection in renal transplant recipients: the role of once-daily tacrolimus in the UK. Journal of Medical Economics, 2015, 18, 1050-1059.	2.1	10
21	Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16). Applied Health Economics and Health Policy, 2019, 17, 615-627.	2.1	10
22	A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK. Journal of Medical Economics, 2020, 23, 593-602.	2.1	10
23	Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US. Journal of Medical Economics, 2016, 19, 672-683.	2.1	9
24	An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 9-18.	1.9	9
25	The Prime Diabetes Model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus. Value in Health, 2017, 20, 985-991.	0.3	8
26	A UK analysis of the cost of switching renal transplant patients from an immediate-release to a prolonged-release formulation of tacrolimus based on differences in trough concentration variability. Journal of Medical Economics, 2014, 17, 520-526.	2.1	7
27	Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. Journal of Medical Economics, 2018, 21, 144-151.	2.1	7
28	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Advances in Therapy, 2019, 36, 1190-1199.	2.9	7
29	The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. Journal of Medical Economics, 2022, 25, 393-402.	2.1	7
30	A long-term analysis evaluating the cost-effectiveness of biphasic insulin lispro mix 75/25 and mix 50/50 versus long-acting basal insulin analogs in the United States. Journal of Medical Economics, 2012, 15, 766-775.	2.1	6
31	An analysis of product wastage arising from dosing increment granularity in four modern growth hormone administration devices. Expert Opinion on Drug Delivery, 2015, 12, 353-360.	5.0	6
32	Evaluating the Cost-Effectiveness of Prolonged-Release Tacrolimus Relative to Immediate-Release Tacrolimus in Liver Transplant Patients Based on Data from Routine Clinical Practice. Drugs - Real World Outcomes, 2016, 3, 61-68.	1.6	6
33	Evaluating the cost-effectiveness of insulin detemir versus neutral protamine Hagedorn insulin in patients with type 1 or type 2 diabetes in the UK using a short-term modeling approach. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 217-226.	2.4	6
34	A cost-utility analysis of SIR-Spheres Y-90 resin microspheres versus best supportive care in the treatment of unresectable metastatic colorectal cancer refractory to chemotherapy in the UK. Journal of Medical Economics, 2020, 23, 1588-1597.	2.1	6
35	A systematic literature review and network meta-analysis of first-line treatments for unresectable hepatocellular carcinoma based on data from randomized controlled trials. Expert Review of Anticancer Therapy, 2021, 21, 341-349.	2.4	6
36	Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. Diabetes Research and Clinical Practice, 2015, 109, 95-103.	2.8	5

#	Article	IF	Citations
37	Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weeklyÂDulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis. Advances in Therapy, 2020, 37, 4446-4457.	2.9	5
38	A UK Analysis of the Cost-Effectiveness of Humalog Mix75/25 and Mix50/50 Versus Long-Acting Basal Insulin. Advances in Therapy, 2012, 29, 1051-1066.	2.9	4
39	Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. Applied Health Economics and Health Policy, 2018, 16, 357-366.	2.1	4
40	Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. Diabetes Therapy, 2018, 9, 87-99.	2.5	4
41	Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert Review of Anticancer Therapy, 2020, 20, 997-1009.	2.4	4
42	Intravenous iron for the treatment of iron deficiency anemia in China: a patient-level simulation model and cost-utility analysis comparing ferric derisomaltose with iron sucrose. Journal of Medical Economics, 2022, 25, 561-570.	2.1	4
43	Laparoscopic adjustable gastric banding vs standard medical management in obese patients with type 2 diabetes: a budget impact analysis in the UK. Journal of Medical Economics, 2013, 16, 249-259.	2.1	3
44	Shortâ€term costâ€utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9). Diabetes, Obesity and Metabolism, 2019, 21, 1706-1714.	4.4	3
45	Development of a Resource Impact Model for Clinics Treating Pre-Operative Iron Deficiency Anemia in Ireland. Advances in Therapy, 2020, 37, 1218-1232.	2.9	3
46	An evaluation of the budget impact of a new 20% subcutaneous immunoglobulin (Ig20Gly) for the management of primary immunodeficiency diseases in Switzerland. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 223-229.	1.9	2
47	Cost-Effectiveness Of The SQ^{Â®} Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective . ClinicoEconomics and Outcomes Research, 2019, Volume 11, 637-649.	1.9	2
48	Product wastage from modern human growth hormone administration devices: a laboratory and computer simulation analysis. Medical Devices: Evidence and Research, 2013, 6, 107.	0.8	1
49	Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in Therapy, 2019, 36, 1821-1825.	2.9	1
50	Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 835-841.	1.9	0
51	Modeling Chronic Kidney Disease in TypeÂ2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts. Diabetes Therapy, 2022, 13, 651-677.	2.5	0
52	Economic Analysis of Intravenous Iron in Patients with Iron Deficiency Anemia Due to Inflammatory Bowel Disease: Considerations for Clinicians [Letter]. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 163-165.	1.9	0